(Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.)
Oramed Pharmaceuticals (NASDAQ:ORMP) is a technology pioneer in delivering insulin orally to diabetes patients, which is currently delivered via injection. Other drug makers haven't succeeded yet in developing insulin in the pill form.
Oramed has huge potential in developing diabetes drugs in oral form and its stock has significant upside potential too. Oramed is currently trading around $6.80 with a market cap of approximately $50 million. It's a micro-cap company, and investors should note that there are risks inherent in micro-cap investing.
Oramed is seeking to revolutionize the treatment of diabetes mellitus through its proprietary flagship product, an
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|